Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00104026 · ClinicalTrials.gov registry record
Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth
A clinical trial of Gingival Overgrowth, sponsored by National Institute of Dental and Craniofacial Research (NIDCR).
- Completed
- Registry status
- 45
- Enrollment target
- 1
- Study location
NCT00104026: Completed study of Gingival Overgrowth, sponsored by National Institute of Dental and Craniofacial Research (NIDCR).
NCT00104026 is a study of Gingival Overgrowth that has completed, run by National Institute of Dental and Craniofacial Research (NIDCR). The registered enrollment target is 45 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00104026, a study of Gingival Overgrowth, has completed, sponsored by National Institute of Dental and Craniofacial Research (NIDCR).
- COMPLETED
- Registry status
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine common features of gingival overgrowth (excessive growth of the gums around the teeth) that develops in patients with the hereditary form of the condition and in those who develop the condition as a side effect of medications. A better understanding of gingival overgrowth may help scientists develop medications with fewer oral side effects. Patients of any age with hereditary gingival fibromatosis and their blood relatives, and patients of any age with gingival overgrowth who are taking medications associated with development of the disorder, including phenytoin (diphenylhydantoin or Dilantin), cyclosporine, and calcium-channel blockers, may be eligible for this study. Participants undergo a medical and dental history, including a history of medication use; detailed examination of the teeth, periodontium, head, and neck; photographs of teeth with gingival overgrowth; dental x-rays; and blood tests. DNA is extracted from a blood sample to look for genes related to gingival overgrowth. Patients with gingival overgrowth are offered two options, as follows: * Tissue biopsy: A tissue sample is taken from each affected site, with a maximum of three biopsies. For the procedure, lidocaine is first injected into the gum to numb the tissue. Then, a cookie-cutter instrument is pushed into the numbed skin, and a small piece of tissue is removed. * Gingivectomy: Surgical removal of the overgrown gingival.
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-02-15 |
| Est. Completion | 2011-04-19 |
What the finished NCT00104026 record still lists
NCT00104026 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 45 participants, a relatively small participant target.
The record links to 1 condition, with Gingival Overgrowth appearing as the primary indexed condition, and to 0 interventions.
NCT00104026 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00104026 about?
NCT00104026 is a clinical study titled "Genes Associated With Hereditary and Drug-Induced Gingival Overgrowth". This study will examine common features of gingival overgrowth (excessive growth of the gums around the teeth) that develops in patients with the hereditary form of the condition and in those who develop the condition as a side effect of medications. A better understanding of gingival overgrowth may...
What is the current status of trial NCT00104026?
This trial is currently completed. The enrollment target is 45 participants. The study started on 2005-02-15. Estimated completion is 2011-04-19.
What conditions does trial NCT00104026 study?
This clinical trial studies the following conditions: Gingival Overgrowth.
Who is sponsoring clinical trial NCT00104026?
This trial is sponsored by National Institute of Dental and Craniofacial Research (NIDCR), which has 91 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00104026 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI